Medicine for treating chronic pulmonary heart disease

Abstract

The invention relates to a medicine for treating chronic pulmonary heart disease. The medicine is prepared from the following raw medicinal materials in parts by weight: 10 parts of officinal magnolia bark, 8 parts of tatarian aster root, 10 parts of ephedra herb, 12 parts of Chinese magnoliavine fruit, 8 parts of Chinese hibisci rosae-sinensis flower, 15 parts of danshen root, 14 parts of safflower, 8 parts of akebia stem and 7 parts of Chinese brake herb. The medicine provided by the invention applies the officinal magnolia bark for eliminating dampness, clearing away phlegm, depressing qi and relieving the sensation of fullness, the tatarian aster root for moistening lung and depressing qi, the ephedra herb for freeing lung and relieving asthma, and inducing diuresis to alleviate edema, the Chinese magnoliavine fruit for tonifying kidney and calming mind, the Chinese hibisci rosae-sinensis flower for clearing lung heat and phlegm fire, the danshen root for promoting blood flow to induce menstrual flow, the safflower for promoting blood flow to induce menstrual flow, and dissipating blood stases to relieve pain, the akebia stem for clearing away heart-fire to induce diuresis, and the Chinese brake herb for clearing heat and promoting diuresis. All the medicinal materials are used together to achieve the effects of promoting blood flow to induce menstrual flow, clearing heat and dampness, and treating heart and lung at the same time, and can be used for treating the chronic pulmonary heart disease effectively. A clinical experiment proves that the medicine provided by the invention can be used for treating the chronic pulmonary heart disease safely and effectively.

Description

technical field [0001] The invention relates to a traditional Chinese medicine, in particular to a medicine for treating chronic pulmonary heart disease. Background technique [0002] Chronic cor pulmonale, also known as cor pulmonale, is caused by chronic lesions in the lung tissue, pulmonary arteries, or thorax, resulting in abnormal lung tissue structure and function, resulting in increased pulmonary vascular resistance and increased pulmonary artery pressure, resulting in right heart dilatation and hypertrophy, accompanied by or Heart disease without right heart failure. The vast majority of cor pulmonale patients in my country develop on the basis of chronic bronchitis or emphysema. [0003] The age of the disease is mostly over 40 years old, and the prevalence rate increases with age. The prevalence is high in cold areas, plateau areas, and rural areas. The most common primary diseases are chronic bronchitis and emphysema. Acute attacks are more common in winter an...

AI Technical Summary

Problems solved by technology

However, the treatment is generally only symptomatic treatment, and western medicine has serious side effects on the liver and kidney functions of the human body.